Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29889648 | 1.00 | KMO (0.51) | KMOALDH1A1POLBHRH3PARP1 | |
| SCHEMBL29907656 | 0.89 | KMO (0.60) | KMOALDH1A1POLBHPGDPIK3CA | |
| SCHEMBL322646 | 0.89 | KMO (0.60) | KMOALDH1A1POLBHPGDPIK3CA | |
| SCHEMBL17075525 | 0.87 | KMO (0.59) | KMOALDH1A1POLBHPGDPIK3CA | |
| SCHEMBL27858848 | 0.87 | ALDH1A1 (0.51) | KMOALDH1A1POLBHPGDPIK3CA | |
| SCHEMBL5041190 | 0.85 | HRH3 (0.50) | ALDH1A1HRH3PARP1HPGDKDM4E | |
| SCHEMBL18412787 | 0.84 | ALDH1A1 (0.49) | KMOALDH1A1POLBHPGDPIK3CA | |
| SCHEMBL29546455 | 0.83 | HRH3 (0.49) | ALDH1A1HRH3PARP1HPGDKDM4E | |
| Lithium Ion SCHEMBL17075524 | 0.83 | ALDH1A1 (0.49) | KMOALDH1A1POLBHPGDPIK3CA | |
| SCHEMBL5042063 | 0.81 | HDAC3 (0.51) | HRH3SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654260-A4 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-09-24 | — | — | EP | claimed |
| EP-1654260-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | claimed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | claimed |
| WO-2005011601-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-02-10 | — | — | WO | claimed |
| EP-1654260-A4 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1654260-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005011601-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | APP, BACE1, SNCA | KMO 2260/4885ALDH1A1 2820/4885POLB 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.